Free Trial
→ 2025 could be 'worse than the dot-com bust', says man who predicted 2008 banking crisis (From Stansberry Research) (Ad)
NASDAQ:RNAZ

TransCode Therapeutics 5/15/2023 Earnings Report

TransCode Therapeutics logo
$0.27 -0.08 (-23.58%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.27 0.00 (-0.55%)
As of 04/17/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

TransCode Therapeutics EPS Results

Actual EPS
-$8,712.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TransCode Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TransCode Therapeutics Announcement Details

Quarter
Date
5/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

TransCode Therapeutics' next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

TransCode Therapeutics Earnings Headlines

What is HC Wainwright's Forecast for RNAZ FY2029 Earnings?
April 18 at 3:33 AM | americanbankingnews.com
Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright
April 17 at 11:55 AM | markets.businessinsider.com
They Won’t Tell You This About Gold
Inflation, digital currency, and government policy are quietly eating away at your savings — and most people won't realize it until it's too late. A new underground report, Gold’s Next Move, reveals why gold could be on the edge of a major breakout — and what you should be doing right now to protect your wealth before the next big move hits.
April 18, 2025 | American Alternative (Ad)
Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial
March 28, 2025 | markets.businessinsider.com
TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
March 28, 2025 | finanznachrichten.de
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
March 27, 2025 | prnewswire.com
See More TransCode Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TransCode Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your email.

About TransCode Therapeutics

TransCode Therapeutics (NASDAQ:RNAZ), a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

View TransCode Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles